Status:
COMPLETED
Study of VX-770 on Desipramine
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
In Development for Cystic Fibrosis
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The objective of this study is to evaluate the effects of VX-770 on Desipramine
Eligibility Criteria
Inclusion
- Subjects must be male or female and between 18 and 55 years of age
- Subject must have a body mass index (BMI) from 18 to 30 kg/m2
- Subject must be judged to be in good health
Exclusion
- History of any illness that, in the opinion of the investigator or the subject's general practitioner, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject
- Subjects who have human immunodeficiency virus, hepatitis C, or active hepatitis B
- Female subjects and male subjects with female partner(s) who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of the last dose of study drug
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2010
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01153542
Start Date
June 1 2010
End Date
August 1 2010
Last Update
December 9 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance CRU, Inc.
Daytona Beach, Florida, United States, 32117